Table 5. Clinical studies of the role of 18F-FDG uptake on PET-CT scans in predicting EGFR mutation status.
| Author/year | Ethnicity | No. of patients | Histology | Stage | EGFR mutation | Results * |
|---|---|---|---|---|---|---|
| Huang et al./2010 | Asian (Taiwanese) | 77 | Ad | Clinical IIIB or IV | 49 (64%) | SUVmax ≥ 9.5, EGFR m+ 78% |
| Na et al./2010 | Asian (Korean) | 100 | 53 Ad, 47 non-Ad | Pathological I-IV | 21 (21%) | SUVmax < 9.2, EGFR m+ 40% |
| Mak et al./2011 | White (88% of all) | 100 | 90 Ad, 10 non-Ad | Clinical I-IV | 24 (24%) | SUVmax ≥ 5.0, WT 96% |
| Ko et al./2014 | Asian (Taiwanese) | 132 | Ad | Clinical I-IV | 69 (52%) | SUVmax ≥ 6.0, EGFR m+63% |
| Present study | Asian (Japanese) | 734 | Ad | Pathological I-IV | 334 (46%) | SUVmax ≤ 2.69, EGFR m+ 62% |
* shows threshold SUVmax and positive predictive value of EGFR mutation status.
Ad = adenocarcinoma; m+ = mutation-positive; WT = wild-type.